Autolus Therapeutics plc (AUTL) Cash Flow Statement
Autolus Therapeutics plc (AUTL) generated -$225.6M of operating cash flow over the twelve months to 2026-06-30, spent $7.1M on capital expenditure and had free cash flow of -$232.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AUTLAutolus Therapeutics plcFollow AUTL — free
—
Price chart with a free account
- Market cap
- 409.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2018 Sep 18 | FY2019 Dec 19 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -31.5 | -101.5 | -145.6 | -206.3 | -283.6 | -225.6 | |
| Capital expenditure | 9.1 | 18.3 | 11.0 | 22.1 | 19.0 | -7.1 | |
| Free cash flow | -40.7 | -119.8 | -156.6 | -228.3 | -302.6 | -232.7 |
USD millions · SEC XBRL
Autolus Therapeutics plc — questions
- What is Autolus Therapeutics plc's operating cash flow?
- -$225.6M over the twelve months to 2026-06-30.
- How much does Autolus Therapeutics plc spend on capital expenditure?
- $7.1M over the twelve months to 2026-06-30.
- What is Autolus Therapeutics plc's free cash flow?
- -$232.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Autolus Therapeutics plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.